Recent Updates
Recently added Catalysts
RARE Negative Sentiment Score: 20/100

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Key Takeaway: Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit related to alleged securities fraud impacting investors from August 2023 to December 2025. This comes after the company's Phase 3 clinical trials for its drug setrusumab in treating osteogenesis imperfecta failed to demonstrate effective results, leading to a significant decline in share price and a reassessment of operational plans. Investors affected by the alleged fraud have until April 6, 2026, to apply for lead plaintiff status in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Ultragenyx's Phase 3 studies for setrusumab failed to show significant results.
  • The company's share price plunged approximately 42% following the negative study results.
  • The announcement led to a reevaluation of company operations and potential expense reductions.

Full Press Release Details

NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:
Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more.
CASE DETAILS:   On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.”   On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Tags

Securities Litigation

Frequently Asked Questions

What is the purpose of the Ultragenyx class action lawsuit?

The lawsuit aims to recover losses for Ultragenyx investors affected by alleged securities fraud from August 3, 2023, to December 26, 2025.

What triggered the drop in Ultragenyx's share price?

The share price dropped about 42% after the announcement that setrusumab failed to significantly reduce fracture rates in Phase III studies.

Who should I contact regarding the lawsuit?

Investors can contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or email lewis.kahn@ksfcounsel.com.

What is the deadline to request lead plaintiff status?

The deadline to request lead plaintiff status is April 6, 2026.

Who is representing the investors in this case?

Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is representing the investors.

Last updated: Feb 17, 2026